Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy
MedComm · 2026-08 · 7 (8)
DOI: 10.1002/mco2.70882 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 03.08.2026. Verfasst von Xiao Ge und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering Southeast University Nanjing China. Die Arbeit nennt 417 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The prevailing view of cold tumors as a singular immune‐insensitive state is not merely imprecise, which is clinically misleading. Currently, we contend that cold tumors comprise a heterogeneous spectrum of resistance ecosystems by distinct, coexisting, dominant barriers. We argue that a universal “heating” strategy is unlikely to succeed; instead, durable clinical benefit will depend on barrier‐directed immune reprogramming. We dissect this heterogeneity by linking a set of core mechanistic drivers to canonical hot, immune‑desert, and immune‐excluded phenotypes. The drivers include defective antigen processing and presentation, impaired T‐cell priming, physical exclusion by aberrant vasculature, stromal components, metabolic exhaustion, and adaptive resistance. Our evaluation of emerging conversion strategies focuses not on their novelty but on capacity to neutralize a specific rate‐limiting barrier. We also examine why combination and sequencing are indispensable, highlight translational gaps between preclinical models and human disease and propose a dynamic biomarker framework that extends beyond static PD‐L1 assessment to capture real‐time shifts in dominant barrier. Our central conclusion is that durable cold‐to‐hot conversion will require iterative, biomarker‐guided and barrier‐adaptive interventions that evolve alongside tumor counter‐adaptation. The reframing positions immunotherapy resistance not as a terminal obstacle but as a manageable, dynamic challenge, offering a practical strategy for clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering Southeast University Nanjing China.
- Department of Biomedical Engineering, College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science Nanjing University Nanjing China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ge, X., Han, D., Wang, J., Dai, X., Ma, C., & Chen, F. (2026). Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy. MedComm, 7(8). https://doi.org/10.1002/mco2.70882
Vancouver
Ge X, Han D, Wang J, Dai X, Ma C, Chen F. Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy. MedComm. 2026;7(8). doi:10.1002/mco2.70882
BibTeX
@article{Ge2026,
author = {Ge, Xiao and Han, Dong and Wang, Jing and Dai, Xinyu and Ma, Chen and Chen, Feihong},
title = {Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy},
journal = {MedComm},
year = {2026},
volume = {7},
number = {8},
doi = {10.1002/mco2.70882}
}
EUVIMED